Trials / Recruiting
RecruitingNCT03760575
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance. |
| PROCEDURE | Indocyanine Green (ICG) Image-Guided Surgery | Standard surgery with image guided resection. |
| DRUG | Cisplatin | 75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery. |
| DRUG | Pemetrexed | 500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery. |
Timeline
- Start date
- 2023-01-10
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2018-11-30
- Last updated
- 2025-12-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03760575. Inclusion in this directory is not an endorsement.